Silence Therapeutics (SLN) Revenue & Revenue Breakdown
Silence Therapeutics Revenue Highlights
Latest Revenue (Y)
$43.26M
Latest Revenue (Q)
$12.41M
Main Segment (Y)
Research Collaboration Income
Main Geography (Y)
GERMANY
Silence Therapeutics Revenue by Period
Silence Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $43.26M | 70.47% |
| 2023-12-31 | $25.38M | 44.99% |
| 2022-12-31 | $17.50M | 40.97% |
| 2021-12-31 | $12.41M | 126.59% |
| 2020-12-31 | $5.48M | 2145.49% |
| 2019-12-31 | $244.00K | 100.00% |
| 2018-12-31 | - | -100.00% |
| 2017-12-31 | $16.00K | -97.92% |
| 2016-12-31 | $770.00K | 100.00% |
| 2015-12-31 | - | -100.00% |
| 2014-12-31 | $15.00K | -87.18% |
| 2013-12-31 | $117.00K | -28.22% |
| 2012-12-31 | $163.00K | -76.51% |
| 2011-12-31 | $694.00K | -70.67% |
| 2010-12-31 | $2.37M | 37.32% |
| 2009-12-31 | $1.72M | -22.00% |
| 2008-12-31 | $2.21M | -45.42% |
| 2007-12-31 | $4.05M | 107.86% |
| 2006-12-31 | $1.95M | 282.51% |
| 2005-12-31 | $509.00K | 220.13% |
| 2004-12-31 | $159.00K | -88.17% |
| 2003-12-31 | $1.34M | 16.77% |
| 2002-12-31 | $1.15M | 734.06% |
| 2001-12-31 | $138.00K | -85.61% |
| 2000-12-31 | $959.00K | -30.00% |
| 1999-12-31 | $1.37M | 552.38% |
| 1998-12-31 | $210.00K | 100.00% |
| 1997-12-31 | - | 100.00% |
| 1996-12-31 | - | 100.00% |
| 1995-12-31 | - | - |
Silence Therapeutics generated $43.26M in revenue during NA 2024, up 70.47% compared to the previous quarter, and up 17728.69% compared to the same period a year ago.
Silence Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $12.41M | 491.04% |
| 2023-12-31 | $2.10M | -24.98% |
| 2023-09-30 | $2.80M | -69.27% |
| 2023-06-30 | $9.10M | -19.96% |
| 2023-03-31 | $11.37M | 138.70% |
| 2022-12-31 | $4.76M | 41.35% |
| 2022-09-30 | $3.37M | -7.47% |
| 2022-06-30 | $3.64M | -36.33% |
| 2022-03-31 | $5.72M | 67.60% |
| 2021-12-31 | $3.41M | 8.17% |
| 2021-09-30 | $3.16M | 16.85% |
| 2021-06-30 | $2.70M | -14.09% |
| 2021-03-31 | $3.14M | -473.40% |
| 2020-12-31 | $-842.00K | -142.35% |
| 2020-09-30 | $1.99M | 246.95% |
| 2020-06-30 | $573.00K | - |
Silence Therapeutics generated $12.41M in revenue during Q1 2024, up 491.04% compared to the previous quarter, and up 260.36% compared to the same period a year ago.
Silence Therapeutics Revenue Breakdown
Silence Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| Research Collaboration Income | $43.10M | $24.80M | $16.90M | $12.02M |
| Royalty Income | $100.00K | $600.00K | $600.00K | - |
Latest
Silence Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Research Collaboration Income (99.77%), and Royalty Income (0.23%).
Silence Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| GERMANY | $144.00K | $569.00K | $578.00K | $392.00K |
Latest
Silence Therapeutics's latest annual revenue breakdown by geography, as of Dec 24: GERMANY (100.00%).
Silence Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TARS | Tarsus Pharmaceuticals | $182.95M | $48.12M |
| CTMX | CytomX Therapeutics | $138.10M | $33.43M |
| GLUE | Monte Rosa Therapeutics | $75.62M | $4.70M |
| SLN | Silence Therapeutics | $43.26M | $12.41M |
| GNFT | Genfit | $28.57M | $17.08M |
| CCCC | C4 Therapeutics | $20.76M | - |
| RNA | Avidity Biosciences | $10.90M | $2.04M |
| STTK | Shattuck Labs | $5.72M | $1.61M |
| IGMS | IGM Biosciences | $2.68M | $516.00K |
| CDTX | Cidara Therapeutics | $1.27M | - |
| APLT | Applied Therapeutics | $455.00K | $144.00K |
| OPT | Opthea | $108.41K | $61.27K |
| CGEM | Cullinan Oncology | - | - |
| NUVL | Nuvalent | - | - |
| PRLD | Prelude Therapeutics | - | - |
| CNTA | Centessa Pharmaceuticals | - | - |
| MLYS | Mineralys Therapeutics | - | - |